Variable | Normal glomeruli | Mesangioproliferative | Proliferative /Necrotizing | Crescentic | Sclerosing | p-value |
---|---|---|---|---|---|---|
Number of patients | 33 | 80 | 46 | 7 | 48 | |
Clinical parameters | ||||||
Age (years) | 41 ± 14.4 | 42.9 ± 13.6 | 40.4 ± 11 | 33.3 ± 15.1 | 41.1 ± 10.4 | 0.35 |
Sex (male, %) | 54.5% | 75% | 63% | 28.6% | 68.8% | 0.04 |
Mean arterial pressure (mmHg) | 91 ± 14 | 100 ± 15 | 102 ± 13 | 103 ± 10 | 101 ± 16 | 0.02 |
Serum creatinine (mg/dL) | 1.56 ± 1.87 | 1.72 ± 0.93 | 2.15 ± 1.26 | 2.06 ± 1.24 | 2.7 ± 2.2 | < 0.001 |
eGFR (ml/min/1.73m2) | 74 ± 29 | 59 ± 30 | 49 ± 31 | 54 ± 33 | 40 ± 25 | < 0.001 |
CKD stage (%) | ||||||
• G1 | 36.4% | 17.5% | 8.7% | 14.3% | 6.2% | 0.001 |
• G2 | 33.3% | 30% | 26.1% | 28.6% | 8.3% | |
• G3 | 27.3% | 32.5% | 30.4% | 28.6% | 45.8% | |
• G4 | 3% | 18.8% | 21.7% | 14.3% | 29.2% | |
• G5 | 0% | 1.2% | 13% | 14.3% | 10.4% | |
Albumin (g/dL) | 4.2 ± 0.6 | 4.1 ± 0.5 | 3.9 ± 0.7 | 2.8 ± 1.02 | 4.1 ± 0.4 | 0.001 |
Serum IgA (mg/dL) | 371 ± 182 | 379 ± 183 | 329 ± 86 | 246 ± 84 | 322 ± 107 | 0.37 |
Increased serum IgA (% pf pts.) | 25% | 40.4% | 16.7% | 0% | 20.7% | 0.09 |
Serum C3 (mg/dL) | 120.3 ± 30.6 | 115.4 ± 24.2 | 114.7 ± 21.6 | 132.3 ± 26.6 | 113 ± 22.5 | 0.39 |
Decreased serum C3 (% of pts.) | 13.8% | 12.7% | 13.8% | 0% | 13.9% | 0.91 |
IgA/C3 ratio | 3.2 ± 1.6 | 3.5 ± 2.1 | 3.02 ± 0.8 | 1.9 ± 0.4 | 2.9 ± 0.9 | 0.15 |
Hematuria (cells/µL) | 30 (15–49) | 36 (17–97) | 35 (15–83) | 903 (117–1925) | 22 (7–44) | 0.002 |
Hematuria (% of pts) | ||||||
• Absent | 30.3% | 35.9% | 31.8% | 0% | 54.3% | 0.003 |
• Mild | 45.5% | 23.1% | 29.5% | 16.7% | 23.9% | |
• Moderate | 12.1% | 27.9% | 20.5% | 0% | 10.9% | |
• Severe | 12.1% | 23.1% | 18.2% | 83.3% | 10.9% | |
24-h proteinuria (g/24 h) | 0.8 (0.2–1.6) | 1.3 (0.7–2.8) | 2.2 (1.2–4.5) | 8.7 (4.9–11) | 1.7 (1.03–3.2) | < 0.001 |
24-h proteinuria (% of pts) | ||||||
• Proteinuria < 0.75 g/24 h(%) | 48.3% | 24.4% | 9.8% | 0% | 19.6% | < 0.001 |
• Proteinuria 0.75–3.5 g/24 h (%) | 41.4% | 59% | 53.7% | 14.3% | 60.9% | |
• Proteinuria > 3.5 g/24 h (%) | 10.3% | 16.7% | 36.6% | 85.7% | 19.6% | |
Treatment | ||||||
• RAAS blockade(%) | 87.9% | 89.7% | 86% | 71.4% | 89.4% | 0.68 |
• Corticosteroids monotherapy (%) | 33.3% | 50% | 41.9% | 0% | 59.6% | < 0.001 |
• Corticosteroids ± other IS agents (%) | 12.1% | 16.7% | 46.5% | 100% | 19.1% | |
Histological parameters | ||||||
Global glomerulosclerosis (% pf glomeruli) | 0% (0–19) | 5.8% (0-28.5) | 20% (0–33) | 9.3% (0-16.6) | 53.8% (33.3–66.6) | < 0.001 |
Intense C3 staining on IF (% of patients) | 29.6% | 67.6% | 64.9% | 57.1% | 68.3% | 0.009 |
IgA staining on IF (% of patients) | ||||||
• Alone | 40.7% | 25% | 14.7% | 0% | 12.5% | 0.11 |
• IgA + IgG co-deposition | 33.3% | 42.6% | 35.3% | 40% | 40% | |
• IgA + IgM co-deposition | 26% | 32.4% | 50% | 60% | 47.5% | |
Arteriolar hyalinosis (% of patients) | 60.6% | 59.2% | 58.1% | 71.4% | 93.5% | 0.001 |
Arteriosclerosis (% of patients) | 33.3% | 21.1% | 23.3% | 28.6% | 52.2% | 0.006 |
Outcome | ||||||
• Doubling of serum creatinine (%) | 0% | 12.5% | 21.7% | 57.1% | 31.2% | < 0.001 |
• ESRD (%) | 0% | 12.5% | 34.8% | 57.1% | 47.9% | < 0.001 |
• Combined endpoint (%) | 0% | 18.8% | 34.8% | 71.4% | 54.2% | < 0.001 |
eGFR decline* | ||||||
• eGFR change/y (ml/min/1.73m2/y) | + 1.2 (-0.79 to 9.03) | -0.29 (-3.02 to 1.87) | -0.45 (-2.83 to 3.97) | -2.32 (-10.3 to 3.71) | -2.16 (-6.01 to -0.07) | < 0.001 |
• Percentage eGFR change (%) | + 7.1% (3.45 to 30.7) | -4% (-12.9 to 7.31) | -4.27% (-12.3 to 27.6) | -43.3% (-87.4 to 49.8) | -26.4% (-36.3 to 14.2) | < 0.001 |
• eGFR decline > 5 ml/min/y (% of pts.) | 3% | 16% | 16.3% | 42.9% | 37.8% | 0.001 |